Prostatype Genomics AB (PROGEN) Says Medicare Review Ongoing; Timing Uncertain

Prostatype Genomics AB said its Medicare reimbursement process for Prostatype is ongoing, with dialogue now focused on a limited number of remaining issues. There is no set deadline, and the company will not speculate on timing.Material DetailsContext by AI AnalystThis is a mid-process regulatory u…